| Characteristic | Growth rate |
|---|---|
| Skin resurfacing (e.g., dermabrasion, chemical peel, lasers - ablative/non-ablative, microdermabrasion) | 6% |
| Neuromodulator injection* | 4% |
| Hyaluronic acid fillers** | 1% |
| Lip augmentation (with injectable materials) | 1% |
| Non-hyaluronic acid fillers*** | 1% |
| Skin treatment using lasers (e.g., laser hair removal, IPL treatment, laser tattoo removal, treatment of leg veins) | 0% |
| Sclerotherapy | 0% |
| Nonsurgical skin tightening | 0% |
| Noninvasive fat reduction **** | -40% |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
June 2025
United States
2023 to 2024
nearly 1,000
Questionnaire
*(Botox庐, Dysport庐, Xeomin庐, Jeuveau庐, Daxxify庐)
** (e.g., Juvederm Ultra庐, Ultra Plus庐, Voluma庐, Volbella庐, Vollure庐, Restylane Lyft庐, Restylane Silk庐, Belotero庐, Bolvella庐, Restylane庐)
***聽 (e.g., Radiesse庐, Sculptra庐, Bellafill庐, Renuva庐 )
****(e.g., CoolSculpting庐, Liposonix庐 , Emsculpt庐, Vanquish庐, Zerona庐, Kybella庐 )
(e.g., Pelleve庐, Thermage庐, Ulthera庐)
Both procedures (HA fillers for lip augmentation and weight loss prescription) include data from ASPS members as well as non-member dermatologists and otolaryngologists.
The source includes the following information: 鈥淟ip Augmentation with HA Filler鈥 was collected as a distinct procedure for the first time in 2024. In prior years, these procedures may have been reported under 鈥淟ip Augmentation with Injectable Materials.鈥 The two categories should not be combined due to potential overlap and risk of double counting"
